Search | Clinical Trials Finder

Conditions: Hemophilia A
Interventions: Antihemophilic factor, recombinant, manufactured protein-free; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 8
States / cities: Little Rock, Arkansas • Los Angeles, California • Peoria, Illinois + 5 more

Conditions: Congenital Bleeding Disorder, Haemophilia A
Interventions: turoctocog alfa; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 6 Months to 70 Years · Male only
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 13
States / cities: Phoenix, Arizona • Long Beach, California • Tampa, Florida + 10 more

Conditions: Severe Hemophilia A
Interventions: Nuwiq; Drug
Lead sponsor: Octapharma; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Von Willebrand Disease
Interventions: Vonicog alfa, Antihemophilic Factor (Recombinant); Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: Up to 17 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 16
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • Jacksonville, Florida + 12 more

Conditions: Hemophilia A
Interventions: Recombinant coagulation factor (rFVIIIFc); Biological
Lead sponsor: Swedish Orphan Biovitrum; Industry
Eligibility: Male only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Hemophilia A
Interventions: Human-cl rhFVIII, Kogenate FS; Biological
Lead sponsor: Octapharma; Industry
Eligibility: 12 Years to 65 Years · Male only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 6
States / cities: Los Angeles, California • Sacramento, California • Denver, Colorado + 3 more

Conditions: Hemophilia A, Hemophilia B
Interventions: Recombinant Factor VIIa BI (rFVIIa BI); Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 12 Years to 65 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Severe Hemophilia A
Interventions: Human-cl rhFVIII; Biological
Lead sponsor: Octapharma; Industry
Eligibility: 12 Years to 65 Years · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Hemophilia
Interventions: Coagulation Factor VIIa (Recombinant); Biological
Lead sponsor: Laboratoire français de Fractionnement et de Biotechnologies; Industry
Eligibility: 6 Months to 75 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hemophilia A, Hemophilia B
Interventions: ADVATE (Antihemophilic Factor [Recombinant]), RIXUBIS (Coagulation Factor IX [Recombinant]); Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 13 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 17
States / cities: Los Angeles, California • San Diego, California • Aurora, Colorado + 14 more

Conditions: Hemophilia A
Interventions: BIIB031 (rFVIIIFc), FVIII (PK subgroup only); Drug
Lead sponsor: Bioverativ Therapeutics Inc.; Industry
Eligibility: Up to 11 Years · Male only
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 12
States / cities: Los Angeles, California • Sacramento, California • San Diego, California + 9 more

Conditions: Hemophilia A With Inhibitors, Hemophilia B With Inhibitors
Interventions: Coagulation Factor VIIa (Recombinant); Biological
Lead sponsor: rEVO Biologics; Industry
Eligibility: 12 Years to 75 Years · Male only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 5
States / cities: Los Angeles, California • Sacramento, California • Aurora, Colorado + 2 more

Conditions: Hemophilia A
Interventions: PEGylated Recombinant Factor VIII, ITI; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: Up to 5 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 20
States / cities: Phoenix, Arizona • Cupertino, California • Oakland, California + 17 more

Conditions: Hemophilia A
Interventions: Advate (Low Dose), Advate (High Dose), BIVV001 (Low Dose), BIVV001 (High Dose); Biological
Lead sponsor: Bioverativ, a Sanofi company; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 7
States / cities: Los Angeles, California • Indianapolis, Indiana • Iowa City, Iowa + 4 more

Conditions: Hemophilia A
Interventions: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method, PEGylated Recombinant Factor VIII; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: Up to 11 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 12
States / cities: Phoenix, Arizona • Denver, Colorado • Gainesville, Florida + 9 more

Conditions: Hemophilia A
Interventions: Moroctocog alfa (AF-CC); Biological
Lead sponsor: Pfizer; Industry
Eligibility: 6 Months to 15 Years · Male only
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 7
States / cities: Cincinnati, Ohio • Portland, Oregon • Dallas, Texas + 1 more

Conditions: Factor VIII Deficiency
Interventions: efanesoctocog alfa (BIVV001); Biological
Lead sponsor: Bioverativ, a Sanofi company; Industry
Eligibility: 12 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 8
States / cities: Los Angeles, California • San Diego, California • Gainesville, Florida + 4 more

Conditions: Hemophilia A
Interventions: Recombinant antihemophilic factor, plasma/albumin-free method (rAHF-PFM); Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: Up to 1 Year · Male only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Indianapolis, Indiana • New Brunswick, New Jersey

Conditions: Hemophilia B
Interventions: IB1001; Biological
Lead sponsor: Cangene Corporation; Industry
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hemophilia A
Interventions: BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222)); Biological
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 4
States / cities: Davis, California • Boston, Massachusetts • Minneapolis, Minnesota + 1 more

Conditions: Hemophilia A
Interventions: PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene Therapy; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 64 Years · Male only
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 19
States / cities: Mountain View, California • Oakland, California • Palo Alto, California + 5 more

Conditions: Von Willebrand Disease (VWD)
Interventions: Vonicog Alfa, ADVATE; Biological
Lead sponsor: Takeda; Industry
Eligibility: Up to 17 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 11
States / cities: Birmingham, Alabama • Peoria, Illinois • Indianapolis, Indiana + 8 more

Conditions: Hemophilia A
Interventions: Recombinant Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM); Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: Up to 6 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 17
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 14 more

Conditions: Hemophilia A
Interventions: Antihemophilic factor, recombinant, manufactured protein-free; Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 10 Years and older · Male only
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 11
States / cities: Aurora, Colorado • Atlanta, Georgia • Peoria, Illinois + 7 more

Search by objective public record fields.

Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A

Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015

Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study

A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies

Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A

Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen

Study to Investigate the Long-term Efficacy and Safety of Human-cl rhFVIII in Previously Treated Patients (PTPs)

LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures

Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS

Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A

Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors

A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A

A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)

BAX 855 Pediatric Study

Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII

A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A

Early Prophylaxis Immunologic Challenge (EPIC) Study

Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia B

Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration

Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults

A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)

Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients

Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901